#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Pulmonary arterial hypertension Frostbite Juvenile idiopathic arthritis Liposarcoma recurrent Partial lipodystrophy Dermatitis Hyperadrenocorticism Acute on chronic liver failure Thrombocytopenia Fungal infection Bronchopulmonary aspergillosis Mitochondrial myopathy Endometrial cancer recurrent Guillain-Barre syndrome Propionic acidaemia More trials…

    Learn about Rare Diseases

    Langerhans cell sarcoma – Diagnostics Focal segmental glomerulosclerosis – Diagnostics Familial amyotrophic lateral sclerosis – Basic Information Gastrointestinal stromal tumour – Basic Information Mantle cell lymphoma stage II – Diagnostics Factor VIII deficiency Activated PI3 kinase delta syndrome – Basic Information Primary hyperoxaluria – Basic Information Waldenstrom’s macroglobulinaemia recurrent Marginal zone lymphoma refractory – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    RO7268489 Alx148 Bdc-1001 Blomia Tropicalis Gad20-209-Fsp-A4 Alitretinoin Anhydrous Cidofovir Neob VOXVOGANAN Lifileucel Azd5863 Emibetuzumab Lamivudine Cls12311 Istem-01 Datopotamab Deruxtecan Oxacillin SAR445399 Bi 1839100 Venetoclax More therapies…

    Learn about Your Condition

    Endotracheal intubation Patent ductus arteriosus Deafness neurosensory Angiosarcoma Hip fracture Autoimmune uveitis BK virus infection Tertiary adrenal insufficiency Urticaria cholinergic Malignant oligodendroglioma Streptococcal infection Intestinal ischaemia Obstructive pancreatitis Renal transplant Actinic cheilitis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Non-small cell lung cancer stage I

  • A Phase 3 Randomized Study of mRNA‑4157 plus Pembrolizumab as Adjuvant Therapy in Patients with Completely Resected Stage I Non‑Small Cell Lung Cancer

    Recruiting

    3 1
    Investigated Diseases:
    • Non-small cell lung cancer stage I
    Investigated Drugs:
    • Mrna-4157
    • Pembrolizumab
    France Germany Greece Hungary Italy The Netherlands +2

  • Study on Datopotamab Deruxtecan and Rilvegostomig for Stage I Non-Small Cell Lung Cancer Patients with ctDNA-Positive or High-Risk Features

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer stage I
    Investigated Drugs:
    • Rilvegostomig
    • Carboplatin
    • Cisplatin
    Belgium France Germany Hungary Italy The Netherlands +3

  • Study on Chemotherapy with Paclitaxel, Cisplatin, and Carboplatin for Patients with Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Lung neoplasm malignant
    • Non-small cell lung cancer stage I
    • Non-small cell lung cancer stage II
    Investigated Drugs:
    • Vinorelbine Tartrate
    • Carboplatin
    • Cisplatin
    France Germany

  • Study on the Effectiveness and Safety of Osimertinib for Patients with Stage IB-IIIA Non-Small Cell Lung Cancer After Tumor Removal

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Non-small cell lung cancer stage I
    • Non-small cell lung cancer stage II
    • Non-small cell lung cancer stage III
    Investigated Drugs:
    • Osimertinib
    Belgium France Germany Italy Poland Spain +1

  • Study on the Safety and Effectiveness of Stereotactic Body Radiotherapy with or without Pembrolizumab for Patients with Unresected Stage I or II Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Pembrolizumab
    Austria France Germany Hungary Italy The Netherlands +4

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!